BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...hit a broader range of antigens than peripheral blood-derived CAR Ts (see “ WindMIL: T cell Source...
BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

Genentech identifies blood as source of antitumor T cells In a Nature article , a Genentech Inc. team reported that non-exhausted T cell clones in the blood could act as a source of antitumor T cells...
BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

WindMIL is developing cancer therapies using bone marrow-derived T cells, which could be more persistent than tumor-infiltrating lymphocytes and hit a broader range of antigens than CAR therapies engineered with peripheral blood T cells. The...
BioCentury | Jan 14, 2020
Emerging Company Profile

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The company is...
BioCentury | Nov 1, 2019
Tools & Techniques

Draper’s devices take on cell therapy’s pain points

Having surveyed more than 60 cell therapy developers on what keeps them up at night, The Charles Stark Draper Laboratory Inc. is building a suite of microfluidic and acoustic tools to overcome the inefficiencies that...
BioCentury | Jul 1, 2019
Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

...expects to close one or two deals this year. A more readily available, less expensive cell source...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
BioCentury | Feb 1, 2019
Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
BioCentury | Mar 9, 2018
Product R&D

Chips for tox

...proof-of-concept studies with pharma partners this year (see “Organ-on-a-Chip Companies”). Table: Organ-on-a-chip companies Company Products Cell source...
Items per page:
1 - 10 of 40
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...hit a broader range of antigens than peripheral blood-derived CAR Ts (see “ WindMIL: T cell Source...
BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

Genentech identifies blood as source of antitumor T cells In a Nature article , a Genentech Inc. team reported that non-exhausted T cell clones in the blood could act as a source of antitumor T cells...
BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

WindMIL is developing cancer therapies using bone marrow-derived T cells, which could be more persistent than tumor-infiltrating lymphocytes and hit a broader range of antigens than CAR therapies engineered with peripheral blood T cells. The...
BioCentury | Jan 14, 2020
Emerging Company Profile

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The company is...
BioCentury | Nov 1, 2019
Tools & Techniques

Draper’s devices take on cell therapy’s pain points

Having surveyed more than 60 cell therapy developers on what keeps them up at night, The Charles Stark Draper Laboratory Inc. is building a suite of microfluidic and acoustic tools to overcome the inefficiencies that...
BioCentury | Jul 1, 2019
Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

...expects to close one or two deals this year. A more readily available, less expensive cell source...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
BioCentury | Feb 1, 2019
Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
BioCentury | Mar 9, 2018
Product R&D

Chips for tox

...proof-of-concept studies with pharma partners this year (see “Organ-on-a-Chip Companies”). Table: Organ-on-a-chip companies Company Products Cell source...
Items per page:
1 - 10 of 40